Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS)

• Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS) - Feb 03, 2022
• Heart Failure - Jun 03, 2021
• ACE-Is, ARBs, DRI, and Sacubitril-Valsartan Scan - May 25, 2017

• ACE-Is, ARBs and DRIs DERP Scan Summary - Jan 29, 2015
• ACEI Derp Scan - Jan 30, 2014
• ACEI/ARB/DRI Scan Summary - Jan 30, 2014
• Class Update: ACEIs, ARBs, DRIs - Jan 26, 2012

• Duplicate Therapy Drug Evaluation - Dec 01, 2022

• February 2026 - Chronic Kidney Disease Pharmacotherapy: Guideline Updates & Practical Application
• September 2025 - 2025 American College of Cardiology/American Heart Association Joint Committee Clinical Practice Guideline Update
• September 2021 - Updates in Heart Failure Therapy: New Drugs and Indications

• December 2015 - Does Sacubitril/Valsartan Pose a Treatment Conundrum for Management of Heart Failure?
• June 2015 - New Hypertension Guidelines: Do Blood Pressure Goals Need to Change with Age?

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.